Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month

FORT MYERS, Fla., June 13, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in Fort Myers, NeoGenomics serves over 600,000 patients each year and is on a mission to serve one million patients annually by 2028.

"With studies suggesting that 1 in 2 men and 1 in 3 women will be diagnosed with cancer in their lifetime,¹ our role as a leading oncology testing services company is more crucial than ever," said Chris Smith, CEO at NeoGenomics. "Receiving this proclamation from the mayor is a testament to the hard work and dedication of our teammates in realizing our goals. At NeoGenomics, we strive to deliver cancer testing options and information that empowers providers to better diagnose and treat their patients."

Mayor Anderson will formally announce the proclamation during the City Council meeting on June 17. NeoGenomics’ CEO, Chris Smith, will be in attendance to accept the honor and bring attention to June as National Cancer Survivors Month. The declaration acknowledges NeoGenomics’ commitment to supporting cancer patients and survivors.

"The City of Fort Myers is thrilled to have NeoGenomics as a community partner and industry leader in transforming care for cancer patients, both internationally and right here in Southwest Florida," said Kevin Anderson, Mayor for the City of Fort Myers. "We look forward to the proclamation this month and to recognizing NeoGenomics’ contributions to supporting so many residents in our region."

The Mayor’s proclamation follows NeoGenomics’ signing of the Working with Cancer Pledge, which showcases their dedication to supporting team members who are living with cancer or caring for a loved one with the disease. These initiatives show the company’s dedication to fighting for and supporting those affected by cancer.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Reference:

1. National Cancer Institute, https://www.cancer.gov/about-cancer/understanding/statistics

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613164016/en/

Contacts

For further information, please contact:
NeoGenomics, Inc. Investors:
Kendra Sweeney
kendra.sweeney@neogenomics.com

Media:
Andrea Sampson
Sampson Public Relations Group
asampson@sampsonprgroup.com